102 related articles for article (PubMed ID: 16310933)
21. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
22. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.
Schulz WA; Alexa A; Jung V; Hader C; Hoffmann MJ; Yamanaka M; Fritzsche S; Wlazlinski A; Müller M; Lengauer T; Engers R; Florl AR; Wullich B; Rahnenführer J
Mol Cancer; 2007 Feb; 6():14. PubMed ID: 17280610
[TBL] [Abstract][Full Text] [Related]
23. The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation.
Lind GE; Skotheim RI; Fraga MF; Abeler VM; Henrique R; Saatcioglu F; Esteller M; Teixeira MR; Lothe RA
Mol Cancer; 2005 Feb; 4(1):8. PubMed ID: 15691383
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells.
Thomas MA; Hodgson MC; Loermans SD; Hooper J; Endersby R; Bentel JM
J Cell Biochem; 2006 Dec; 99(5):1409-19. PubMed ID: 16817226
[TBL] [Abstract][Full Text] [Related]
25. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression.
Akamatsu S; Takata R; Ashikawa K; Hosono N; Kamatani N; Fujioka T; Ogawa O; Kubo M; Nakamura Y; Nakagawa H
Hum Mol Genet; 2010 Nov; 19(21):4265-72. PubMed ID: 20716579
[TBL] [Abstract][Full Text] [Related]
26. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
Preece DM; Harvey JM; Bentel JM; Thomas MA
Prostate; 2011 Mar; 71(4):403-14. PubMed ID: 20842667
[TBL] [Abstract][Full Text] [Related]
27. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.
Abdulkadir SA
Ann N Y Acad Sci; 2005 Nov; 1059():33-40. PubMed ID: 16382041
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of NKX3.1 in benign prostatic hyperplasia.
Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
[TBL] [Abstract][Full Text] [Related]
30. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer.
Kindich R; Florl AR; Jung V; Engers R; Müller M; Schulz WA; Wullich B
Clin Chem; 2005 Mar; 51(3):649-52. PubMed ID: 15738520
[No Abstract] [Full Text] [Related]
31. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
Bethel CR; Bieberich CJ
Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
33. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR
Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
[TBL] [Abstract][Full Text] [Related]
35. [Association of prostate cancer with PDLIM5, SLC22A3 and NKX3-1 in Chinese men].
Hui J; Wang JY; Shi XH; Zhang YG; Liu M; Wang X; Wang NN; Chen X; Liang SY; Wei D; Zhao F; Zhang YH; Yang Z
Zhonghua Nan Ke Xue; 2012 May; 18(5):404-11. PubMed ID: 22741436
[TBL] [Abstract][Full Text] [Related]
36. Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size.
Rodriguez Ortner E; Hayes RB; Weissfeld J; Gelmann EP
Urology; 2006 Feb; 67(2):311-5. PubMed ID: 16442598
[TBL] [Abstract][Full Text] [Related]
37. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP.
Zhang HN; Yu CX; Zhang PJ; Chen WW; Jiang AL; Kong F; Deng JT; Zhang JY; Young CY
Acta Pharmacol Sin; 2007 Mar; 28(3):423-30. PubMed ID: 17303007
[TBL] [Abstract][Full Text] [Related]
38. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of NKX3.1 and C-MYC expression in canine prostatic cancer.
Fonseca-Alves CE; Kobayashi PE; Laufer-Amorim R
Res Vet Sci; 2018 Jun; 118():365-370. PubMed ID: 29665565
[TBL] [Abstract][Full Text] [Related]
40. Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor.
Ju JH; Maeng JS; Zemedkun M; Ahronovitz N; Mack JW; Ferretti JA; Gelmann EP; Gruschus JM
J Mol Biol; 2006 Jul; 360(5):989-99. PubMed ID: 16814806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
